<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02998840</url>
  </required_header>
  <id_info>
    <org_study_id>AVB244-003</org_study_id>
    <nct_id>NCT02998840</nct_id>
  </id_info>
  <brief_title>A Prospective Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Elevated Blood Pressure</brief_title>
  <official_title>A Prospective, Vehicle Controlled, Double Blinded, Multicenter, Randomized, Phase II Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Elevated Blood Pressure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AOBiome LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Veristat, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AOBiome LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate and compare the efficacy of B244 in treating
      patients with hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Prospective, Vehicle Controlled, Double Blinded, Multicenter, Randomized Phase II
      trial, comparing the effect of twice daily B244 application for 4 weeks vs vehicle
      application on BP and inflammatory biomarkers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Actual">June 26, 2017</completion_date>
  <primary_completion_date type="Actual">April 25, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>Baseline-6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in mean in clinic systolic BP between the active and vehicle groups</measure>
    <time_frame>Baseline-Week 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in mean in clinic diastolic BP between the active and vehicle group</measure>
    <time_frame>Baseline-Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in mean ambulatory systolic and diastolic daytime blood pressure</measure>
    <time_frame>Baseline-Week 4</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Difference in inflammatory biomarkers between active and vehicle groups</measure>
    <time_frame>Baseline-Week 4</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Microbial content</measure>
    <time_frame>Baseline, Day 28, Day 42</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Microbial composition</measure>
    <time_frame>Baseline, Day 28, Day 42</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">132</enrollment>
  <condition>Prehypertension</condition>
  <condition>Hypertension, Stage I</condition>
  <arm_group>
    <arm_group_label>B244 4 pumps applied to the face</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 pumps total of spray to saturate the entire face. Applications should occur in the morning and at night for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle 4 pumps applied to the face</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>4 pumps total of spray to saturate the entire face. Applications should occur in the morning and at night for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B 244 8 Pumps applied to face and torso</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>8 pumps total - 4 pumps of spray to saturate the entire face and 4 pumps to the torso Applications should occur in the morning and at night for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle 8 pumps applied to face and torso</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>8 pumps total - 4 pumps of spray to saturate the entire face and 4 pumps to the torso Applications should occur in the morning and at night for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>B244</intervention_name>
    <description>odorless suspension</description>
    <arm_group_label>B244 4 pumps applied to the face</arm_group_label>
    <arm_group_label>B 244 8 Pumps applied to face and torso</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>odorless suspension</description>
    <arm_group_label>Vehicle 4 pumps applied to the face</arm_group_label>
    <arm_group_label>Vehicle 8 pumps applied to face and torso</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects ≥18 years of age

          -  In good general health as determined by a thorough medical history and physical
             examination, and vital signs

          -  Clinical diagnosis of elevated Blood Pressure defined as:

               -  Having systolic prehypertension measurements having systolic BP (mmHg) of 120-139
                  and Diastolic BP (mmHg) of 90

               -  OR

               -  Having systolic Stage 1 hypertension measurements having systolic BP (mmHg) of
                  140-159 and Diastolic BP (mmHg) of 100

          -  Hypertension treatment naïve patients, defined as those patients who have never been
             treated with antihypertensive medications or have been off any hypertensive treatment
             for a period of 12 weeks or longer.

          -  Willing to refrain from using any antihypertensive treatments, other than the
             investigational product, including herbal supplements, systemic use of steroids,
             chronic use of NSAIDS, any antihypertensive agents, such as beta-blockers, diuretics,
             ACE inhibitors, CA channel blockers, Alpha blockers, Central Acting agents and
             vasodilators.

          -  Ability to comprehend and comply with procedures

          -  Agree to commit to participate in the current protocol

          -  Provide written informed consent prior to any study procedure being performed (all
             subjects should be able to understand the informed consent form and any other
             documents that subjects are required to read)

        Exclusion Criteria:

          -  Pregnant and/or lactating women

          -  Patients on treatment for Benign Prostatic Hyperplasia (BPH)

          -  Clinically significant history of cardiovascular disease (i. e. PCI, CABG MI (if event
             occurred 12 months), atrial fibrillation, frequent PAC, cardiac rhythm disorder,
             syncope, valve repair/replacement, heart transplantation, PTA, peripheral bypass
             surgery, endarterectomy, unstable angina, TIA, stroke and NYHF category II, II and IV
             heart failure.

          -  Patients with renal failure, significant kidney or renal disease defined as having
             creatinine level of mg/dL

          -  Presence of any condition (medical, psychological, social, or geographical), actual or
             anticipated, that the Investigator feels would restrict or limit the patient's
             successful participation for the duration of the study

          -  History of migraines and/or anxiety, where patient is unable to refrain from the use
             of beta blockers

          -  History of sensitivity to any of the study medications, or components thereof or a
             history of drug or other allergy that, in the opinion of the Investigator or Medical
             Monitor, contraindicates their participation.

          -  The participant has been previously randomized in this study

          -  Subjects with clinical diagnosis of Type I Diabetes

          -  Subjects with arm circumference of 42 cm

          -  Any condition that would prevent the subject from participating in the trial in the
             opinion of the evaluation physician

          -  The participant has received an investigational product within 30 days prior to
             randomization

          -  Prior use of any product containing B244 or Nitrosomonas eutropha

          -  Unable to lie flat or sit for 15 minutes

          -  Concurrent participation in other trials
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Larry Weiss, MD</last_name>
    <role>Study Director</role>
    <affiliation>Chief Medical Officer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Central Research Associates</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elite Clinical Studies</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orange County Research Center</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Consulting</name>
      <address>
        <city>Milford</city>
        <state>Connecticut</state>
        <zip>06460</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AGA Clinical Trials</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICCT Research International</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedPharmics</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alternative Primary Care (Einstein Clinical Research)</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20190</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHEAR Center</name>
      <address>
        <city>The Bronx</city>
        <state>New York</state>
        <zip>10459</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Trials WorldWide</name>
      <address>
        <city>Humble</city>
        <state>Texas</state>
        <zip>77338</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2016</study_first_submitted>
  <study_first_submitted_qc>December 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2016</study_first_posted>
  <last_update_submitted>June 27, 2017</last_update_submitted>
  <last_update_submitted_qc>June 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>elevated blood pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prehypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

